SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/02/23
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual MeetingGlobeNewsWire • 11/01/23
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/02/23
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/23
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell TumorsGlobeNewsWire • 05/30/23
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual MeetingGlobeNewsWire • 05/25/23
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation SummitGlobeNewsWire • 05/24/23
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 CongressGlobeNewsWire • 05/11/23
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/03/23
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care ConferenceGlobeNewsWire • 05/02/23
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/17/23
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023Business Wire • 04/17/23
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/17/23
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023Business Wire • 04/17/23
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid TumorsGlobeNewsWire • 03/08/23
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 03/01/23
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/28/23
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid TumorsGlobeNewsWire • 02/27/23
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/09/23